Urolithin A

Used for

Mitophagy — the "second phase" of mitochondrial support

Urolithin A works through a different mechanism than CoQ10 or PQQ: rather than supporting existing mitochondria (CoQ10) or creating new ones (PQQ's biogenesis effect), Urolithin A activates mitophagy — the selective clearance of damaged, worn-out mitochondria. This is why it's used as a second-phase addition rather than a first-line mitochondrial tool: it clears out the old before the biogenesis/support tools build up the new. Clearing out damaged mitochondria helps the remaining ones use glucose and fatty acids more efficiently, which in turn reduces oxidative stress and cellular damage — the same downstream damage that can otherwise cycle back into elevated hs-CRP or contribute to cell membrane damage.

Common form & typical benefits

Codeage Liposomal Urolithin A (combination formula)

What the research says

Evidence by outcome

This is one of the newest compounds in this library, and the honest picture reflects that: the mechanism is well-confirmed at the human biomarker level (genes and proteins actually changing the way the theory predicts), and muscle strength specifically has a real placebo-controlled win behind it. But several of the "harder" performance outcomes (aerobic capacity, walking distance) haven't yet cleared the placebo-controlled bar, even though they moved favorably. This is a compound with strong mechanistic support and one solid functional outcome, not yet the broad multi-outcome evidence base that something like Magnesium or CoQ10 has built up over decades.

All of the trial data above is for isolated Urolithin A. The product used here also delivers resveratrol, betaine, and CoQ10 in the same capsule — each with a separate evidence base of its own, but the specific combination hasn't been studied together as a single intervention.

Dosages used in studies

What the research actually tested

Worth checking total CoQ10 intake if this is used alongside the CoQ10 supplement elsewhere in this framework — this product already contributes 60 mg per day on its own.

Safety notes & high-dose risks

What to watch for

• Favorable safety profile in trials so far — the Phase 1 trial's primary purpose was specifically testing safety, and no serious or product-related adverse effects were recorded, including at higher doses.
• Well tolerated up to 1,000 mg/day for 4 months — the longest and largest human trial to date found no significant safety concerns. This is for isolated Urolithin A; the added resveratrol, betaine, and CoQ10 in this product each have their own separate, generally favorable safety profiles as well.
• Still a newer compound overall — long-term data (years, not months) doesn't yet exist. Worth being upfront that "no problems so far" reflects a few years of relatively limited human research, not decades.
• CoQ10 overlap: since this product already contains 60 mg of CoQ10, factor that into total daily CoQ10 intake if also using the standalone CoQ10 supplement in this framework — including the warfarin interaction noted on the CoQ10 page.

Additional notes

Worth knowing

• Positioned as the "second phase" in this framework — mitophagy (clearing damaged mitochondria) pairs logically after or alongside CoQ10 (supporting existing function) and PQQ (building new mitochondria), rather than replacing either.
• Dietary sources are unreliable: ellagitannin-rich foods (pomegranate, walnuts, berries) only convert to Urolithin A via gut bacteria, and this conversion varies hugely between individuals — direct supplementation bypasses that variability.
• Interesting dose-response wrinkle: the lower 500mg dose outperformed the 1,000mg dose on muscle strength in the largest trial — worth knowing that "more" didn't clearly mean "better" here, unlike a simple linear dose-response.
• Retesting: there's no single lab marker for Urolithin A status specifically — response is tracked through functional measures (strength, endurance) alongside the markers it indirectly supports, such as hs-CRP, given the oxidative-stress connection.